mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

被引：4

作者：

Garcia-Beltran, Wilfredo F. ^{[1
,2
]}

St Denis, Kerri J. ^{[2
]}

Hoelzemer, Angelique ^{[3
,4
,5
]}

Lam, Evan C. ^{[2
]}

Nitido, Adam D. ^{[2
,6
]}

Sheehan, Maegan L. ^{[2
]}

Berrios, Cristhian ^{[1
]}

Ofoman, Onosereme ^{[1
]}

Chang, Christina C. ^{[7
,8
]}

Hauser, Blake M. ^{[2
]}

Feldman, Jared ^{[2
,6
]}

Roederer, Alex L. ^{[2
,6
]}

Gregory, David J. ^{[9
,10
]}

Poznansky, Mark C. ^{[9
,11
]}

Schmidt, Aaron G. ^{[2
]}

Iafrate, A. John ^{[1
]}

Naranbhai, Vivek ^{[8
,11
,12
]}

Balazs, Alejandro B. ^{[2
]}

机构：

[1] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

[2] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA

[3] Univ Med Ctr Eppendorf, Dept Internal Med 1, Div Infect Dis, Hamburg, Germany

[4] German Ctr Infect Res DZIF, Site Hamburg Lubeck Borstel Riems, Braunschweig, Germany

[5] Leibniz Inst Expt Virol, Res Dept Virus Immunol, Hamburg, Germany

[6] Harvard Med Sch, Div Med Sci, PhD Program Virol, Boston, MA 02115 USA

[7] Monash Univ, Alfred Hosp, Cent Clin Sch, Prahran, Vic 3181, Australia

[8] Ctr AIDS Programme Res South Africa, ZA-4001 Durban, South Africa

[9] Massachusetts Gen Hosp, Vaccine & Immunotherapy Ctr, Boston, MA 02129 USA

[10] Massachusetts Gen Hosp Children, Pediat Infect Dis, Boston, MA 02114 USA

[11] Massachusetts Gen Hosp Canc Ctr, Boston, MA 02114 USA

[12] Dana Farber Canc Inst, Boston, MA 02215 USA

来源：

CELL | 2022年 / 185卷 / 03期

关键词：

ANTIBODY;

D O I：

10.1016/j.cell.2021.12.033

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured the neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild-type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that received their primary series recently (<3 months), distantly (6-12 months), or an additional "booster"dose, while accounting for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinees. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron, only 4-6-fold lower than wild type, suggesting enhanced cross-reactivity of neutralizing antibody responses. In addition, we find that Omicron pseudo virus infects more efficiently than other variants tested. Overall, this study highlights the importance of additional mRNA doses to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.

引用

页码：457 / +

页数：15

共 50 条

[31] A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern
van Gils, Marit J.
van Willigen, Hugo D. G.
Wynberg, Elke
Han, Alvin X.
van der Straten, Karlijn
Burger, Judith A.
Poniman, Meliawati
Oomen, Melissa
Tejjani, Khadija
Bouhuijs, Joey H.
Verveen, Anouk
Lebbink, Romy
Dijkstra, Maartje
Appelman, Brent
Lavell, A. H. Ayesha
Caniels, Tom G.
Bontjer, Ilja
van Vught, Lonneke A.
Vlaar, Alexander P. J.
Sikkens, Jonne J.
Bomers, Marije K.
Russell, Colin A.
Kootstra, Neeltje A.
Sanders, Rogier W.
Prins, Maria
de Bree, Godelieve J.
de Jong, Menno D.
CELL REPORTS MEDICINE, 2022, 3 (01)
[32] Neutralizing antibodies against the SARS-CoV-2 Omicron variant following two CoronaVac vaccinations and a Pfizer/BioNTech mRNA vaccine booster
da Silva, Almir Ribeiro, Jr.
Villas-Boas, Lucy Santos
de Paula, Anderson Vicente
Tozetto-Mendoza, Tania Regina
Honorato, Layla
Witkin, Steven S.
Mendes-Correa, Maria Cassia
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, 2022, 64
[33] Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine
Saharia, Kapil K.
Husson, Jennifer S.
Niederhaus, Silke, V
Iraguha, Thierry
Avila, Stephanie, V
Yoo, Youngchae J.
Hardy, Nancy M.
Fan, Xiaoxuan
Omili, Destiny
Crane, Alice
Carrier, Amber
Xie, Wen Y.
Vander Mause, Erica
Hankey, Kim
Bauman, Sherri
Lesho, Patricia
Mannuel, Heather D.
Ahuja, Ashish
Mathew, Minu
Avruch, James
Baddley, John
Goloubeva, Olga
Shetty, Kirti
Dahiya, Saurabh
Rapoport, Aaron P.
Luetkens, Tim
Atanackovic, Djordje
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2022, 11 (05)
[34] Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant
Zhou, Zhongcheng
Du, Peng
Li, Ning
Xiong, Xinxin
Tang, Shengjun
Dai, Qinjin
Wang, Taorui
Yu, Meixing
Man, Miao
Lam, Kelvin
Baptista-Hon, Daniel T.
Tai, Wa Hou
Monteiro, Olivia
Ng, Weng Sam
Lee, Un Man
Liu, Zhihai
Zhang, Kang
Li, Gen
MEDCOMM, 2022, 3 (02):
[35] The fourth COVID-19 vaccine dose increased the neutralizing antibody response against the SARS-CoV-2 Omicron (B.1.1.529) variant in a diverse Brazilian population
Farias, Jessica Pires
Andreata-Santos, Robert
Brito, Ruth Dalety da Silva
Souza, Milena Silva
Fogaca, Mayanna Moreira Costa
Pinheiro, Josilene Ramos
da Cruz, Edgar Ferreira
Liang, Willian
Simoes, Rafael da Conceicao
Luiz, Wilson Barros
Birbrair, Alexander
Vidal, Paloma Oliveira
Maricato, Juliana Terzi
Braconi, Carla Torres
Ferreira, Luis Carlos de Souza
Janini, Luiz Mario Ramos
Amorim, Jaime Henrique
MICROBIOLOGY SPECTRUM, 2023,
[36] mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
Gruell, Henning
Vanshylla, Kanika
Tober-Lau, Pinkus
Hillus, David
Schommers, Philipp
Lehmann, Clara
Kurth, Florian
Sander, Leif E.
Klein, Florian
NATURE MEDICINE, 2022, 28 (03) : 477 - +
[37] mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
Henning Gruell
Kanika Vanshylla
Pinkus Tober-Lau
David Hillus
Philipp Schommers
Clara Lehmann
Florian Kurth
Leif E. Sander
Florian Klein
Nature Medicine, 2022, 28 : 477 - 480
[38] Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico
Antonio Montes-Gonzalez, Jose
Arturo Zaragoza-Jimenez, Christian
Eduardo Antonio-Villa, Neftali
Fermin-Martinez, Carlos A.
Ramirez-Garcia, Daniel
Vargas-Vazquez, Arsenio
Idania Gutierrez-Vargas, Rosaura
Garcia-Rodriguez, Gabriel
Lopez-Gatell, Hugo
Ivan Valdes-Ferrer, Sergio
Yaxmehen Bello-Chavolla, Omar
FRONTIERS IN PUBLIC HEALTH, 2023, 11
[39] Dynamic variations in COVID-19 with the SARS-CoV-2 Omicron variant in Kazakhstan and Pakistan
Qianqian Cui
Zhengli Shi
Duman Yimamaidi
Ben Hu
Zhuo Zhang
Muhammad Saqib
Ali Zohaib
Baikadamova Gulnara
Mukhanbetkaliyev Yersyn
Zengyun Hu
Shizhu Li
Infectious Diseases of Poverty, 12
[40] Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
Rescigno, Maria
Agrati, Chiara
Salvarani, Carlo
Giannarelli, Diana
Costantini, Massimo
Mantovani, Alberto
Massafra, Raffaella
Zinzani, Pier Luigi
Morrone, Aldo
Notari, Stefania
Matusali, Giulia
Pinter, Giuseppe Lauria
Uccelli, Antonio
Ciliberto, Gennaro
Baldanti, Fausto
Locatelli, Franco
Silvestris, Nicola
Sinno, Valentina
Turola, Elena
Lupo-Stanghellini, Maria Teresa
Apolone, Giovanni
FRONTIERS IN IMMUNOLOGY, 2023, 14

← 1 2 3 4 5 →